



BioMmune Technologies Inc. Announces the Appointment of Expert in Biologics as New Director

VANCOUVER, BRITISH COLUMBIA, December 16th, 2014 BioMmune Technologies Inc., (TSX.V:IMU) a company focused on harnessing the body's own immune system to fight cancer and autoimmune diseases, today welcomes Professor Terry Pearson to the Board of Directors of BioMmune Technologies Inc.

Dr. Pearson is a Professor in the Department of Biochemistry and Microbiology at the University of Victoria. He obtained his PhD in Immunology under the supervision of Professors Julia Levy and Doug Kilburn from the University of British Columbia. He undertook postdoctoral work at the Medical Research Council Laboratory in Cambridge, England in the laboratory of Nobel Prize winner Sydney Brenner. While in Cambridge collaborated with Nobel Prize winner César Milstein where he was involved in the early stages of development of monoclonal antibodies and hybridoma technologies. This technology underpins most of the current biologic therapeutics used for the treatment of human diseases including cancer and autoimmune diseases such as arthritis.

For more than 35 years his research has focused on the immunology, and biochemistry of tropical diseases, mainly African sleeping sickness and on biomarkers and diagnosis of disease. Over the past decade, his research has focused on translation of basic research discoveries into application to clinical diagnostic medicine in both the developed and developing world. He is the Vice President of Research and Development and co-Founder of SISCAPA Assay Technologies, Inc., a biotechnology company that is developing transformative clinical diagnostic assays for monitoring health and disease. He is a University of Victoria Legacy award recipient for his research achievements. Dr. Pearson currently serves on the boards of several private and public biotechnology companies.

"In addition to Dr. Karoly Nikolich, Dr. Pearson will be a good addition and complement the scientific expertise of the board of bioMmune Technologies Inc." said Dr. Reinhard Gabathuler, President of bioMmune Technologies Inc.

ABOUT BIOMMUNE

BioMmune Technologies Inc. is a biopharmaceutical company headquartered in Vancouver, Canada. BioMmune is developing three technologies discovered at The University of British Columbia. They include, discovery of compounds that will be active in restoring immune-recognition of cancer cells resulting in the body's immune system to fight the cancer cells. A discovery relating to Channels, whose activities regulate activity of cells involved in the immune system to improve their ability to combat cancers, infections and also autoimmunities. Furthermore, the company is pursuing the modulation of CD74, a protein

involved in the immune system and its ability to fight foreign antigens. Finding ways or compounds that regulate its activity will improve the immune system to combat infections, cancers and autoimmune diseases. BioMmune trades on the TSX Venture Exchange under the symbol "IMU".

Forward Looking Statements

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may we may not be successful in either preclinical or clinical trials and not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

On Behalf of the Board of Directors
Dr. Reinhard Gabathuler, President
1 (514) 963-6177
gaba@biommune.net

"Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release"